Form 8-K - Current report:
SEC Accession No. 0000950170-23-058199
Filing Date
2023-11-02
Accepted
2023-11-02 16:10:11
Documents
14
Period of Report
2023-11-02
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rlay-20231102.htm   iXBRL 8-K 44056
2 EX-99.1 rlay-ex99_1.htm EX-99.1 210348
3 GRAPHIC img175089203_0.jpg GRAPHIC 7375
  Complete submission text file 0000950170-23-058199.txt   389453

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rlay-20231102_lab.xml EX-101.LAB 12806
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rlay-20231102.xsd EX-101.SCH 2454
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rlay-20231102_pre.xml EX-101.PRE 9443
8 EXTRACTED XBRL INSTANCE DOCUMENT rlay-20231102_htm.xml XML 4526
Mailing Address 399 BINNEY STREET 2ND FLOOR CAMBRIDGE MA 02139
Business Address 399 BINNEY STREET 2ND FLOOR CAMBRIDGE MA 02139 617-370-8837
Relay Therapeutics, Inc. (Filer) CIK: 0001812364 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39385 | Film No.: 231372367
SIC: 2836 Biological Products, (No Diagnostic Substances)